ReviewFrontiers in neurology2019
Cell-Based Therapies for Stroke: Are We There Yet?
Review in Frontiers in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 64 citations in OpenAlex.
- Trial
- Small-molecule-induced neuron-specific hypoxia: recapitulating developmental angiogenesis for ischemic stroke therapy.Acta pharmacologica Sinica · 2026Article
- Progress in Intra-Arterial Stem Cell Therapy for Ischemic Stroke: A Review.Stroke (Hoboken, N.J.) · 2026Review
- A review: Carrier-based hydrogels containing bioactive molecules and stem cells for ischemic stroke therapy.Bioactive materials · 2025Review
- Brain repair mechanisms after cell therapy for stroke.Brain : a journal of neurology · 2024Review
- Advancements in the mechanisms of Naotai formula in treating stroke: A multi-target strategy.Heliyon · 2024Review
- Stem cell therapy: a new hope for stroke and traumatic brain injury recovery and the challenge for rural minorities in South Carolina.Frontiers in neurology · 2024Review
- Preconditioning with interleukin-1 alpha is required for the neuroprotective properties of mesenchymal stem cells after ischemic stroke in mice.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Article
- Article
- Engineered Extracellular Vesicles Derived from Dermal Fibroblasts Attenuate Inflammation in a Murine Model of Acute Lung Injury.Advanced materials (Deerfield Beach, Fla.) · 2023Article
- Inflammation and immunomodulation in central nervous system injury - B cells as a novel therapeutic opportunity.Neurobiology of disease · 2023Review
- Protection against brain injury after ischemic stroke by intravenous human amnion epithelial cells in combination with tissue plasminogen activator.Frontiers in neuroscience · 2023Article
- Hyperacute transplantation of umbilical cord mesenchymal stromal cells in a model of severe intracerebral hemorrhage.Future science OA · 2022Article
- Biodegradable Microparticles for Regenerative Medicine: A State of the Art and Trends to Clinical Application.Polymers · 2022Review
- The Role of Interstitial Fluid Pressure in Cerebral Porous Biomaterial Integration.Brain sciences · 2022Article
- Neurofunctional and neuroimaging readouts for designing a preclinical stem-cell therapy trial in experimental stroke.Scientific reports · 2022Article
- Molecular and anatomical roadmap of stroke pathology in immunodeficient mice.Frontiers in immunology · 2022Article
- Current status of ischemic stroke treatment: From thrombolysis to potential regenerative medicine.Regenerative therapy · 2021Review
- Article
- Cell therapy strategies for COVID-19: Current approaches and potential applications.Science advances · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke is the second leading cause of death and physical disability, with a global lifetime incidence rate of 1 in 6. Currently, the only FDA approved treatment for ischemic stroke is the administration of tissue plasminogen activator (tPA). Stem cell clinical trials for stroke have been underway for close to two decades, with data suggesting that cell therapies are safe, feasible, and potentially efficacious. However, clinical trials for stroke account for <1% of all stem cell trials. Nevertheless, the resources devoted to clinical research to identify new treatments for stroke is still significant (53-64 million US$, Phase 1-4). Notably, a quarter of cell therapy clinical trials for stroke have been withdrawn (15.2%) or terminated (6.8%) to date. This review discusses the bottlenecks in delivering a successful cell therapy for stroke, and the cost-to-benefit ratio necessary to justify these expensive trials. Further, this review will critically assess the currently available data from completed stroke trials, the importance of standardization in outcome reporting, and the role of industry-led research in the development of cell therapies for stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.